

Ayyappa Chaturvedula, PhD, FCP
Email: ayyappach@gmail.com

EDUCATION	<ul style="list-style-type: none">• Fellow, CDDS-UCSF, Department of Biopharmaceutical Sciences, UCSF, Georgetown Campus, Washington DC (Mar 2009-Mar 2011)• Ph.D., Department of Pharmaceutical Sciences, Mercer University, Atlanta GA 30341 USA [May' 2001 – Mar' 2005] (THESIS: Pharmacokinetic evaluation of skin transport technologies)• B. Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, AP, India [Sep' 1996 – Nov' 2000].
WORK EXPERIENCE	<ul style="list-style-type: none">• Sr. Director, Clinical Pharmacology, Arcus Biosciences, Hayward, CA USA [July 2023-Present]• Sr. Director, Pharmacometrics Consulting, Pumas AI, Inc. [Jan 2022- June 2023]• Director, Clinical Pharmacology, Arcus Biosciences, Hayward, CA, USA [June 2021- Dec 2021]• Associate Professor (part-time), Pharmacotherapy, College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX [June 2021-Present]• Associate Professor, Pharmacotherapy, College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX [September 2015-May 2021]• Associate Professor, Medical Education, TCU-UNTHSC School of Medicine, University of North Texas Health Science Center, Fort Worth, TX [Dec 2019-Present]• General Manager, Informatics and Analytics, GVK Biosciences Pvt Ltd. Hyderabad, India. [July 2014-August 2015]• Director, Center for Pharmacometrics, Dept of Pharmacy Practice, Mercer University, College of Pharmacy and Health Sciences, Atlanta, GA [Dec 2011-2014]• Assistant Professor, Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30345 [July 2012-June 2014]• Visiting Research Assistant Professor, Department of Pharmacy Practice, College of Pharmacy and

	<p>Health Sciences, Mercer University, Atlanta, GA 30345 [July 2011-July 2012]</p> <ul style="list-style-type: none"> • Sr. Development Scientist, Venture Group, GlaxoSmithKline, Parsippany, NJ 07054 [Jul' 2008-June 2011] • Sr. Scientist, Clinical Pharmacokinetics, Schering Plough, Kenilworth NJ 07054 [Mar' 2007-Jul'2008] • Sr. Development Scientist, New Product Development, GlaxoSmithKline, Parsippany, NJ 07054 [Mar' 2005-Feb'2007]
TECHNICAL SKILLS	<ul style="list-style-type: none"> • Advanced training in pharmacometrics • Model Informed Drug Development (MIDD) • Software skills: Proficient with NONMEM, Pumas, R, S-Plus and Phoenix, familiar with SAS and SPSS
DRUG DELIVERY RESEARCH EXPERIENCE	<ul style="list-style-type: none"> • Expertise in development of drug delivery systems (Transdermal, and Nasal) • Designing and conducting in vitro and in vivo transdermal delivery studies • Expertise in Microdialysis sampling techniques to characterize absorption kinetics using transdermal delivery systems
CLINICAL PHARMACOLOGY AND DRUG DEVELOPMENT EXPERIENCE	<ul style="list-style-type: none"> • Lead pharmacokineticist on small and large molecular drug development programs at Schering Plough • Served as pharmacometrician on HIV prophylaxis research with NIH based network sponsored studies • Clinical pharmacology member of clinical study teams in immunotherapy drug development programs • Clinical pharmacology and pharmacometrics consultant to various drug development programs at Pumas AI in multiple therapeutic areas • Experienced in MIDD study reports, dossier preparation for regulatory interactions, responding to regulatory questions related to clinical pharmacology and pharmacometrics
INTERPERSONAL SKILLS	<ul style="list-style-type: none"> • Excellent verbal and written communications skills • Experience in working with KOLs on collaborative research programs • Trained in tools of creativity and ideation and experience in leading and participating ideation sessions and team building activities • Trained in project management tools

	<ul style="list-style-type: none"> • Experience working in complex matrix environment within Consumer healthcare and Pharmaceutical R&D organizations • Experience in establishing legal contracts with external companies and academic institutions. • Involved in negotiations of contracts with external parties in the event of conflict
MANAGEMENT EXPERIENCE	<ul style="list-style-type: none"> • Successfully recruited and managed post-doctoral fellows (PhD and PharmD) and graduate students • Managed research contracts as Principal Investigator • Managing a team of high caliber pharmacometricians at Pumas AI, Inc.
RESEARCH GRANTS (Academic Career)	<ul style="list-style-type: none"> • Supplement Sub-award (\$53, 698 co-Investigator) on “Application of PBPK models to inform dosing recommendations for hormonal contraceptives co-administered with other medications” (June 2018-May 2021) {Prime funder: Gates Foundation, Prime PI- University of Florida} • HIV Prevention Trial Network (HPTN)- Laboratory Core- Sub-award (\$168, 021) (12/01/2020-05/31/2021) • R01 Sub-award (\$340,811, co-Investigator) on “Improving PrEP protection of Transgender women through mechanistic pharmacokinetic understanding” (03/2019-05/2021). • Sub-award (\$370,292 co-Investigator) on “Application of PBPK models to inform dosing recommendations for hormonal contraceptives co-administered with other medications” (June 2018-May 2020) {Prime funder: Gates Foundation, Prime PI- University of Florida} • UNTHSC start up grant (Sep 2015-Sep 2018) • R01 Sub-award (\$219,746) on NIH RO1 “Real World Adherence to HIV PrEP in Serodiscordant African Couples” (June 2016- May 2019) • A grant (\$59,375) was awarded by GlaxoSmithKline for conducting research project: “Biopharmaceutical evaluation and development of IVIVR for nicotine formulations” (2012-2013 and 2013-2014) • A grant (\$15,408) was awarded by GlaxoSmithKline for conducting research project: “IVIVC development for paracetamol tablet formulations” (2012-2013) • A grant (\$38,029) was awarded by Johns Hopkins University for conducting research project:

	<p>“Development of population pharmacokinetic models for tenofovir”</p> <ul style="list-style-type: none"> • A grant (\$57,296) was awarded by Massachusetts General Hospital for conducting research project: “Population pharmacokinetic analysis of tenofovir concentrations from Partner’s PreP trial”(2013-2014) • A grant (\$50,000) was awarded by LTS pharmaceuticals for conducting research project: “PK modeling and simulation work on nominated compounds/formulations” (2013-2014) • Sub-award on NIH RO1 “Real World Adherence to HIV PrEP in Serodiscordant African Couples” (2013-2014, 5 year renewable grant)
<p>PEER-REVIEWED PUBLICATIONS</p>	<ol style="list-style-type: none"> 1. R Conjeevaram, A Chaturvedula, Guru V. Betagiri, Gangadhar Sunkara and Ajay K. Banga. Iontophoretic In Vivo Transdermal Delivery of β-Blockers in Hairless Rats and Reduced Skin Irritation by Liposomal Formulation, Pharm Res, 20(9), 2003, 1496-1501. 2. A Chaturvedula, D.P. Joshi, C. Anderson, R. Morris, and A. Banga, “Dermal, subdermal and systemic concentrations of granisetron by iontophoretic delivery” Pharm Res , 22 (8), 2005, 1313-1319. 3. A Chaturvedula, D.P. Joshi, C. Anderson, R. Morris, Walter Sembrowich and A. Banga, In Vivo Iontophoretic Delivery and Pharmacokinetics of Salmon Calcitonin Int. J. Pharm, 2005, 297 (1-2), 190-6. 4. A Chaturvedula, A. K. Banga, IVIVC of transdermal drug delivery. Book Chapter, Pgs 155-176,ISBN: 0849338271. 5. Kasha PC, Anderson CR, Morris RL, Sembrowich WL, Chaturvedula A, Banga AK. Subcutaneous concentrations following topical iontophoretic delivery of diclofenac. Drug Discov Ther. 2012 Oct;6(5):256-62. 6. Abla MJ, Chaturvedula A, O'Mahony C, Banga AK. Transdermal delivery of methotrexate for pediatrics using silicon microneedles. Ther Deliv. 2013 May;4(5):543-51. 7. Chaturvedula A, Sale ME, Lee H. Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-

concurrently co-administered with amlodipine. *J Clin Pharmacol.* 2014 Feb;54(2):141-9.

8. **Chaturvedula A**, Fossler MJ, Hendrix CW. Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. *J Clin Pharmacol.* 2013 Nov 6.
9. RN. Burns, **A. Chaturvedula**, DC. Turner, H. Zhang, CM. Van Den Berg. Population Pharmacokinetic Pharmacodynamic Modeling of Caffeine Using Visual Analogue Scales. *Pharmacology & Pharmacy*, 2014, 5, 444-454.
10. K. Madrasi, R.N. Burns, C.W. Hendrix, M.J. Fossler, **A. Chaturvedula**. Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. *CPT Pharmacometrics Syst Pharmacol.* 2014 Nov 12;3:e147.
11. Burns RN, Hendrix CW, **Chaturvedula A**. Population Pharmacokinetics of Tenofovir and Tenofovir-diphosphate in healthy women. *J Clin Pharmacol.* 2015 Jan 8.
12. Lu Y, Goti V, **Chaturvedula A**, Haberer JE, Fossler MJ, Sale ME, Bangsberg D, Baeten JM, Celum CL, Hendrix CW. Population pharmacokinetics of tenofovir in HIV-1 uninfected members of sero-discordant couples and effect of dose reporting methods. *Antimicrob Agents Chemother.* 2016 Jun 27. pii: AAC.00559-16. [Epub ahead of print]
13. Manian M, Madrasi K, **Chaturvedula A**, Banga AK. Investigation of the Dermal Absorption and Irritation Potential of Sertaconazole Nitrate Anhydrous Gel. *Pharmaceutics.* 2016 Jul 7;8(3). pii: E21. doi: 10.3390/pharmaceutics8030021.
14. Madrasi K, **Chaturvedula A**, Haberer JE, Sale M, Fossler MJ, Bangsberg D, Baeten JM, Celum C, Hendrix CW. Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Pre-exposure Prophylaxis. *J Clin Pharmacol.* 2017 May;57(5):606-615.
15. V Goti, **A Chaturvedula**, MJ Fossler, S Mok, and JT Jacob. Hospitalized Patients with and without Hemodialysis Have Markedly Different Vancomycin Pharmacokinetics: A Population

	<p>Pharmacokinetic Model-Based Analysis. <i>Ther Drug Monit.</i> 2018 Apr;40(2):212-221.</p> <p>16. Mallayasamy S, Chaturvedula A, Blaschke T, Fossler MJ. A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study. <i>CPT Pharmacometrics Syst Pharmacol.</i> 2018 Dec;7(12):818-828. doi: 10.1002/psp4.12361. Epub 2018 Oct 28.</p> <p>17. Lesko LJ, Vozmediano V, Brown JD, Winterstein A, Zhao P, Lippert J, Höchel J, Chaturvedula A, White A, Schmidt S Establishing a Multidisciplinary Framework to Study Drug-Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate. <i>CPT Pharmacometrics Syst Pharmacol.</i> 2018;7(11):706-708.</p> <p>18. Chaturvedula, A, Calad-Thomson, S. , Liu, C. , Sale, M. , Gattu, N. and Goyal, N. (2019), Artificial Intelligence and Pharmacometrics: Time to Embrace, Capitalize, and Advance?. <i>CPT Pharmacometrics Syst. Pharmacol.</i>, 8: 440-443. doi:10.1002/psp4.12418.</p> <p>19. Srinivasan, M. , Chaturvedula, A. , Fossler, M. J., Patil, A. , Gota, V. and Prabhash, K. (2019), Population Pharmacokinetics of Pemetrexed in Adult Non–Small Cell Lung Cancer in Indian Patients. <i>The Journal of Clinical Pharmacology.</i> doi:10.1002/jcph.1417.</p> <p>20. Mallayasamy S, Chaturvedula A, Fossler MJ, Sale M, Goti V, Bumpus NN, Marzinke MA, Hendrix CW, Haberer JE, for the Partners Demonstration Project Team. 2019. Tenofovir plasma concentration from preexposure prophylaxis at the time of potential HIV exposure: a population pharmacokinetic modeling and simulation study involving serodiscordant couples in East Africa. <i>Antimicrob Agents Chemother</i> 63:e00446-19. https://doi.org/10.1128/AAC.00446-19.</p> <p>21. Mallayasamy S, Chaturvedula A, Fossler MJ, Sale ME, Hendrix CW and Haberer JE (2019) Assessment of Demographic and Socio-Behavioral Factors on Adherence to HIV Pre-Exposure Prophylaxis Using a Markov Modeling Approach. <i>Front. Pharmacol.</i> 10:785. doi: 10.3389/fphar.2019.00785.</p> <p>22. Mamun A, Nsiah NY, Srinivasan M, Chaturvedula A, Basha R, Cross D, Jones HP, Nandy K,</p>
--	---

Vishwanatha JK. Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation. *Ethn Dis.* 2019 Jul 18;29(3):517-524. doi: 10.18865/ed.29.3.517.

23. Srinivasan, Meenakshi, Hirani, R, Tsiu, M, Kabani, K, **Chaturvedula, A**; Palasik, B. Utility of Physiologically Based Pharmacokinetic Modeling in Point-of-Care Decisions: An Example Using Digoxin Dosing in Continuous Venovenous Hemodiafiltration, *Therapeutic Drug Monitoring*, 2020 Feb, 42 (1), 1-5 doi: 10.1097/FTD.0000000000000704.
24. **Chaturvedula A**, Palasik BN, Cho HJ and Goyal N (2020) Broader Implications of Modeling and Simulation (M&S) Tools in Pharmacotherapeutic Decisions: A Cautionary Optimism. *Front. Pharmacol.* 11:571. doi: 10.3389/fphar.2020.00571.
25. Srinivasan M, White A, **Chaturvedula A**, Vozmediano V, Schmidt S, Plouffe L, Wingate LT. Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development. *Pharmacoeconomics*. 2020 Oct;38(10):1031-1042. doi: 10.1007/s40273-020-00944-0. PMID: 32734572; PMCID: PMC7578131.
26. Cicali B, Lingineni K, Cristofolletti R, Wendl T, Hoechel J, Wiesinger H, **Chaturvedula A**, Vozmediano V, Schmidt S. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. *CPT Pharmacometrics Syst Pharmacol.* 2021 Jan;10(1):48-58. doi: 10.1002/psp4.12572. Epub 2020 Dec 13. PMID: 33217171; PMCID: PMC7825189.
27. Lingineni, K., **Chaturvedula, A.**, Cicali, B., Cristofolletti, R., Wendl, T., Hoechel, J., Brown, J. D., Vozmediano, V., & Schmidt, S. (2021). Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis Approach. *Clinical pharmacology and therapeutics*, 10.1002/cpt.2457. Advance online publication. <https://doi.org/10.1002/cpt.2457>
28. Tanaudommongkon A, **Chaturvedula A**, Hendrix CW, Fuchs EJ, Shieh E, Bakshi RP, Marzinke MA. Population pharmacokinetics of tenofovir,

	<p>emtricitabine and intracellular metabolites in transgender women. <i>Br J Clin Pharmacol</i>. 2022 Aug;88(8):3674-3682. doi: 10.1111/bcp.15310. Epub 2022 Mar 25. PMID: 35285974; PMCID: PMC9296590.</p> <p>29. Zhang L, Iannuzzi S, Chaturvedula A, Irungu E, Haberer JE, Hendrix CW, von Kleist M. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women. <i>Nat Med</i>. 2023 Nov;29(11):2753-2762. doi: 10.1038/s41591-023-02615-x. Epub 2023 Nov 13. PMID: 37957377; PMCID: PMC10667095.</p>
<p>RESEARCH PRESENTATIONS (POSTER AND PODIUM)</p>	<ol style="list-style-type: none"> 1. A. Chaturvedula, K.H. Liao, M. Zhao, B. Agoram. Use of a population pharmacokinetic modeling and simulation approach to identify flat doses of Domvanalimab in Phase 3 studies. 2023 annual meeting, American Society of Clinical Pharmacology and Therapeutics. 2. X. Yu, A. Chaturvedula, L. Jin, H. Wu, P. Foster, D. Colburn, R. Criste, B. Agoram. Population Pharmacokinetics of zimberelimab (AB122) and Dose Justification by Model Informed Drug Development (MIDD) Approach. 2021 annual meeting, American Society of Clinical Pharmacology and Therapeutics. 3. M. Srinivasan, A. Chaturvedula, M.J. Fossler, A. Patil, K. Prabhaskar, V. Gota. Population pharmacokinetics of pemetrexed in adult non-small cell lung cancer in Indian patients. <i>J Pharmacokinetics and Pharmacodynamics</i> (2018) 45(Suppl 1): 3. 4. S. Mallayasamy, A. Chaturvedula, M. J. Fossler, M. Sale, V. Goti, C. Hendrix, J. Haberer. Interpretation on the coverage of HIV pre-exposure prophylaxis of once-daily tenofovir regimen in the Partners demonstration project using population pharmacokinetic modeling and simulation. <i>Clinical Pharmacology in Drug Development</i> 7 (S1). 5. S. Mallayasamy, A. Chaturvedula, M. J. Fossler, M. Sale, C. Hendrix, J. Haberer. Assessment of Covariates on Adherence to Tenofovir-based HIV Pre-exposure prophylaxis regimen using Markov modeling approach. <i>Clinical Pharmacology in Drug Development</i> 7 (S1). 6. K. Fairman, M. Srinivasan, A. Chaturvedula. Evaluation of the sensitivity of concluding bioequivalence using population pharmacokinetic

	<p>model-based simulations. <i>Clinical Pharmacology in Drug Development</i> 7 (S1).</p> <ol style="list-style-type: none"> 7. A. Chaturvedula, EI. Ette. On multiple imputation using chained equations (MICE) and missing covariates in population pharmacokinetic analysis. <i>J Pharmacokinet Pharmacodyn</i> (2017) 44:S11–S143. 8. A. Chaturvedula, EI. Ette. Performance of a dummy category (DC) in handling missing covariates in pharmacometric analysis. <i>J Pharmacokinet Pharmacodyn</i> (2017) 44:S11–S143. 9. V. Goti, R. Burns, A. Chaturvedula, E. Ette. Comparison of Model Based and Model Independent Approaches for Handling Data Below the Limit of Quantitation. <i>J Pharmacokinet Pharmacodyn</i> (2015) 42:S11–S107. 10. Y. Lu, V. Goti, A. Chaturvedula, J. Haberer, MJ. Fossler, ME. Sale, D. Bangsberg, J. Baeten, C. Celum, C.W. Hendrix. Population pharmacokinetics of tenofovir in HIV uninfected members of serodiscordant couples and effect of dose reporting methods: An analysis from Partners PrEP study. <i>J. Pharmacokinet Pharmacodynam</i> (2014) 41:S7-S101. (Supplement for ACOP 2014) 11. K. Madrasi, A. Chaturvedula, J. Haberer, M. Sale, M. Fossler, D. Bangsberg, J. Baeten, C. Celum, C.W. Hendrix. Markov mixed effects modeling of adherence using MEMS dosing records from Partners PrEP ancilliary adherence substudy, J. <i>Pharmacokinet Pharmacodynam</i> (2014) 41:S7-S101. (Supplement for ACOP 2014) 12. K. Madrasi, R.N. Burns, C.W. Hendrix, M.J. Fossler, A. Chaturvedula. Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. Presented at 2014 Annual Meeting of American College of Clinical Pharmacology (AACCP), Atlanta, GA. (Student/Trainee Award Winner) 13. R.N. Burns, C.W. Hendrix, M.J. Fossler, A. Chaturvedula. Population Pharmacokinetics of Tenofovir and Tenofovirdiphosphate in healthy women Presented at 2014 Annual Meeting of American College of Clinical Pharmacology (AACCP), Atlanta, GA. 14. A Chaturvedula, M.J.Fossler, CW. Hendrix. Assessment of adherence to tenofovir oral administration using simulation strategies, Accepted
--	--

	<p>to present at 2013 Annual Meeting of American College of Clinical Pharmacology (ACCP), Bethesda, 5 MD.</p> <ol style="list-style-type: none"> 15. Chaturvedula, M.J.Fossler, CW. Hendrix. Estimation of population pharmacokinetic parameters of tenofovir using unreliable dosing histories. Accepted to present at 2013 Annual Meeting of American College of Clinical Pharmacology (AACCP), Bethesda, MD. 16. Burns RN, Chaturvedula A, Turner DC, Zhang H, Vandenberg C. Population pharmacokinetic-pharmacodynamic modeling of caffeine using visual analogue scales. Accepted to present at 2013 Annual Meeting of American College of Clinical Pharmacology (ACCP), Bethesda, MD. 17. V. Goti, S. Wilensky, B. Walsh, Chaturvedula A. Development of a Direct Differential Equation Based IVIVC for Paracetamol Immediate Release Formulations. Has been accepted for presentation at the 2013 AAPS conference being held November 10-14, 2013 in San Antonio, Texas. 18. Gaurav Bhatia, Mehtab Abla, Ganesh Deshpande, Ajay Banga, Ayyappa Chaturvedula. Evaluation of alternative membrane models as a surrogate for buccal membrane permeation of nicotine. Has been accepted for presentation at the 2013 CRS conference being held in Honolulu, HI. Chaturvedula, S. Mok, M. Chesson, M.J.Fossler, J.T.Jacob. Population pharmacokinetics (PK) of vancomycin in hospitalized patients. 52 Annual Meeting of ICAAC, San Francisco, CA 2012. 19. Chaturvedula, H.Lee, M. Sale. Development of population pharmacokinetic model for simvastatin and amlodipine interaction guided by single objective hybrid genetic algorithm. 2012 Annual Meeting of American College of Clinical Pharmacology (AACCP), San Diego, CA. 20. J. Coleman, A. Chaturvedula, C. Hendrix, MTN-001 Protocol Team. Method of hormonal contraception is associated with lower tenofovir concentration in healthy women (MTN-001): implications for pre-exposure prophylaxis. : 19th International AIDS Conference: Abstract no. FRLBC03. 21. A Chaturvedula, C. Celum, J Baeten, D Donnell, D Bangsberg, J. Haberer, A Mujugira, C. Hendrix. Development of population pharmacokinetic model
--	--

	<p>for Tenofovir using sparsely sampled subject data. Poster presented at the annual meeting of Population Approach Group in Europe (PAGE), June 4-6, 2012 in Venice, Italy.</p> <p>22. A Chaturvedula, N. Metzger, MJ. Fossler, M. Jann, “Development of population pharmacokinetic model of vancomycin using single trough collected during routine therapeutic drug monitoring” Accepted at 2012 Annual Meeting of American College of Clinical Pharmacology and Therapeutics (ASCPT), Maryland.</p> <p>23. A Chaturvedula, S. Dipali, S. Paliwal, S. Mitragotri, “Sonophoresis to Enhance Skin Bioavailability of Acyclovir and nDocosanol” Presented at 2011 Annual Meeting of American Association of Pharmaceutical Scientists, October 23-27, Washington DC.</p> <p>24. N Metzger, F Mirza, K Momary, A Chaturvedula, “Incidence of Supratherapeutic Trough Concentrations in Elderly Patients with Aggressive Vancomycin Dosing”, Presented at 2011 Annual Meeting of American College of Clinical Pharmacy, October 16-19, Pittsburgh, PA.</p> <p>25. A Chaturvedula, C. Anderson, R. Morris, and A. Banga, “Characterization of iontophoretic delivery by dermal and subdermal microdialysis” Presented at 2005 Annual Meeting of American Association of Pharmaceutical Scientists, November 6- 10, Nashville, TN.</p> <p>26. A Chaturvedula, D.P. Joshi, C. Anderson, R. Morris, and A. Banga, “IVIVC of iontophoretic delivery of granisetron by microdialysis” Presented at 2004 Annual Meeting of American Association of Pharmaceutical Scientists, October 26-30, Baltimore, MD.</p> <p>27. A Chaturvedula, D.P. Joshi, C. Anderson, R. Morris, Walter Sembrowich and A. Banga, “Evaluation of In Vivo Iontophoretic Delivery of Salmon Calcitonin” Presented as a podium presentation at the 2004 Annual Meeting of Controlled Release Society, June 12-16, Honolulu, Hawaii.</p> <p>28. A Chaturvedula, D.P. Joshi, C. Anderson, R. Morris, and A. Banga, “Evaluation of iontophoretic permeation kinetics of granisetron through skin by subcutaneous microdialysis” Presented at 2003 Annual Meeting of American Association of</p>
--	---

	<p>Pharmaceutical Scientists, October 26-30, Salt Lake City, Utah.</p> <p>29. A Chaturvedula, C. Anderson, R. Morris, and A. Banga, "Evaluation of stereoselective iontophoretic permeation of propranolol through skin by subcutaneous microdialysis" Presented at 2003 Annual Meeting of American Association of Pharmaceutical Scientists, October 26-30, Salt Lake City, Utah.</p> <p>30. A Chaturvedula, A. M. Smith, and A. K. Banga, "Delivery of Opioid Analgesics through Micropores in the Skin" Presented at 2003 Annual Meeting of American Association of Pharmaceutical Scientists, October 26-30, Salt Lake City, Utah.</p> <p>31. D. P. Joshi, A. Chaturvedula, S-L Chang, S. E. Mills, A. M. Smith, and A. K. Banga, "Steady Insulin Infusion via Micropores Through the Stratum Corneum in Hairless Rats" Presented at 2003 Annual Meeting of American Association of Pharmaceutical Scientists, October 26-30, Salt Lake City, Utah.</p> <p>32. A Chaturvedula, R. Conjeevaram, C. Anderson, R. Morris, and A. Banga, "Transdermal Delivery of Propranolol HCl To Hairless Rats Using a Self-Contained Iontophoretic Patch" Presented at 2003 7 Annual Meeting of Controlled Release Society, July 19-23, Glasgow, Scotland.</p> <p>33. R. Conjeevaram, A. Chaturvedula, G. V. Betageri and A. K. Banga, "In Vivo Transdermal Delivery of Beta-Blockers in Hairless Rats." Presented at 2002 Annual Meeting of American Association of Pharmaceutical Scientists, November 10-14, Toronto, Ontario, Canada.</p>
<p>INVITED PRESENTATIONS (SPEAKER/MODERATOR)</p>	<ul style="list-style-type: none"> • Speaker, Invited speaker on "PK Principles and Applications" in course Quantitative Aspects of Drug Action-I at Mercer University, Atlanta, GA 30341 (November 18, 2005) • Moderator, Symposium at the 2006 Annual National Biotech Conference. Topic: Transdermal delivery of proteins and peptides (May 2006) at Boston, MA. • Moderator, Symposium held at the 2008 Annual meeting of American Association of Pharmaceutical Scientists at Atlanta, GA in November 2008. Topic: "Modeling and Simulation Strategies for Evaluation of Drug Safety in Clinical Studies".

	<ul style="list-style-type: none"> • Speaker, Medical All Hands Meeting, GSK CHRD, May 20-21, 2009. Topic: “Population Pharmacokinetics”. • Co-Chair and Speaker, Symposium at the 2012 Annual Meeting of American Association of Clinical Pharmacology (AACCP), San Diego, CA. Topic: “Pharmacometrics influencing the hospital based pharmacotherapeutic decisions” • Co-Chair, Symposium at the 2013 Annual Meeting of ASCPT, Indianapolis, IN. Topic: “Role of pharmacometrics in the development of prophylactic and therapeutic antiviral treatments” • Co-Chair, Symposium at the 2013 Annual Meeting of ACCP, Bethesda, MD. Topic: “Adherence: Missing link in the Puzzle of Clinical Pharmacology” • Co-Chair, Annual meeting of American College of Clinical Pharmacology 2014, Atlanta, GA. • ACCP Education Committee Member: 2010-Present • Steering committee member of Asian Pharmacometric Network (APN) • Co-Chair, Symposium at the 2017 annual meeting of ACCP, San Diego, CA. Topic: “Modeling of Adherence: Applications in Drug Development and Clinical Practice” • Co-Chair and Speaker, Symposium at the 2017 annual meeting of ACOP, Fort Lauderdale, FL. Topic: “Adherence to Medications: A Crucial Missing Link in Quantitative Clinical Pharmacology” • Co-Chair, Symposium at the 2017 annual meeting of ACOP, Fort Lauderdale, FL. Topic: “Healthcare Analytics and Pharmacometrics - Bench to Bedside Progression- Opportunities for Synergy” • Co-Chair, Symposium at the 2018 annual meeting of ACOP, San Diego, CA. Topic: “AI and Pharmacometrics: Time to Embrace, Capitalize and Advance” • Co-Chair, Annual meeting of American College of Clinical Pharmacology 2020, Bethesda, MD.
<p>PROFESSIONAL ACTIVITIES INCLUDING LEADERSHIP ROLES</p>	<ul style="list-style-type: none"> • ACCP Education Committee Member: 2010-Present • Visiting Scientist in Department of Biopharmaceutical Sciences, University of

	<p>California in San Francisco (UCSF): Apr 2009- Mar 2011</p> <ul style="list-style-type: none"> • Chair for ‘Scientific Discussions’ at GlaxoSmithKline, Parsippany, NJ [Aug’ 2005-2007] • Research Mentor for a Senior High School Student (Kimberly Oo, currently at Harvard University) in GlaxoSmithKline’s Summer Intern Program (2005) • Adjunct Faculty in Mercer University, Dept of Pharmaceutical Sciences [2005-2007] • Chair, American Association of Pharmaceutical Scientists (AAPS) Student chapter of Mercer University [June’ 2003 – June’ 2004] • Chair, Fundraising Committee of annual meeting of GRASP (Graduate Research Association of Students in Pharmacy) [June’ 2003-June’ 2004]
AWARDS AND HONORS	<ul style="list-style-type: none"> • Best poster presentation award in GRASP 2003, Richmond, VA for the poster “Transdermal Delivery of Propranolol HCl to Hairless Rats Using a Self-Contained Iontophoretic Patch” A. Chaturvedula, R. Conjeevaram, C. Anderson, R. Morris, and A. Banga. • Acknowledged by AAPS for the outstanding performance as AAPS student chapter chair at Mercer University, 2003. • Bornze Spirit Award at GlaxoSmithKline (2006) for the team spirit in a combination product development project • Shining Performance award at Schering-Plough (2007) for the development of PK model for designing of clinical protocol for drug interaction of SCH417690 (CCR5 inhibitor) with CYP3A4 inhibitors • Shining Performance award at Schering-Plough (2008) for the development of Population PK model for SCH420814 (A2A receptor inhibitor) and validation using bootstrapping. • Outstanding student abstract at 2014 Annual Meeting of ACCP (Dr. Kumpal Madrasi-postdoc) • “Excellence in Achievement” acknowledgement by American College of Clinical Pharmacology, August 2017 • Best poster award from Institute of Patient Safety, 2018 annual Research Appreciation Day, UNTHSC (Dr. Meenakshi Srinivasan- Postdoc)

	<ul style="list-style-type: none"> • Best poster award Clinical Research, 2018 annual Research Appreciation Day, UNTHSC (Dr. Surulivelrajan Mallayasamy- Postdoc) • Outstanding student abstract at 2018 Annual Meeting of ACCP (Dr. Surulivelrajan Mallayasamy- postdoc) • 2020 Tanabe Young Investigator award by the American College of Clinical Pharmacology • Graduated ACCP's leadership development program 2022 (The Achieve Institute)
ACADEMIC ADVISING	<ul style="list-style-type: none"> • Dr. Rebecca Burns – Currently working in Medical Affairs, Arbor Pharmaceuticals, Atlanta, GA. • Dr. Kumpal Madrasi- Currently working at Applied Biomath, Boston, MA. • Dr. Yanhui Lu- Currently working at the US FDA as Clinical Pharmacology Reviewer • Dr. Vineet Goti- Currently working at Nuventra as pharmacometrician. • Dr. Eric Mintah- Pharmacometrics consultant • Dr. Surulivelrajan Mallayasamy- Currently working as Associate Professor, Manipal University, India • Dr. Meenakshi Srinivasan- Currently working at GSK • Dr. Asama Tanaudommongkon- Currently working at Teva
TEACHING EXPERIENCE	<ul style="list-style-type: none"> • PHAR 7343- Pharmacokinetics (3Cr) delivered to PY2 PharmD students • PHAR 7117- Pharmaceutical Calculations (1 Cr) delivered to PY1 PharmD students • Teaching faculty, Certificate in Pharmacometrics program at UNTHSC
PROFESSIONAL MEMBERSHIPS	<ul style="list-style-type: none"> • AACP (American Association of Clinical Pharmacology) • ASCPT (American Society of Clinical Pharmacology and Therapeutics) • ISOP (International Society of Pharmacometrics)
SERVED AS JOURNAL REVIEWER	<ul style="list-style-type: none"> • Plos Computation Biology • Journal of Clinical Pharmacology • Critical Reviews in Therapeutic Drug Carrier Systems • Journal of Physics and Chemistry of Solids • Acta Pharmacologica Sinica • Frontiers in Pharmacology • Pharmacometrics and Systems Pharmacology • Journal of Pharmacokinetics and Pharmacodynamics

	<ul style="list-style-type: none">• European Journal of Pharmaceutical Sciences
REFERENCES	AVAILABLE ON REQUEST